Global survey reveals top workforce concerns, evolving strategic priorities, and key technology investment areas for life sciences manufacturers
MVA-BN approved for use against mpox and smallpox in adolescents 12-17 years of age after expedited review with EMA
Doses will be ready to ship to applicable European Union (EU) member states as soon as possible upon European Commission (EC) authorization
ALS patients experience neuroinflammation and rapid neurodegeneration
The trial met its primary and secondary endpoints demonstrating that administration of a 3-dose regimen of GARDASIL 9
The study observed 2,648 girls, of which 2,300 completed the standard 45-day programme
The recent inspection covered both cGMP and PAI processes
Phase 3 study results will form the basis for future discussions with global regulatory authorities
The new Injectable Facility housed in Akums Healthcare started commercial production on 22nd August 2024, with a capacity of 362 million units annually
Approval based on MIRACLE Phase III trial demonstrating a significant and clinically meaningful reduction in asthma exacerbations and improvement in asthma symptom control
Subscribe To Our Newsletter & Stay Updated
